Phase II and UGT1A1 genotype study of irinotecan dose escalation as salvage therapy for advanced gastric cancer

British Journal of Cancer, 04/24/2012

Individualised irinotecan dose escalation based on patient tolerance was not associated with increased toxicity and shows modest activity as salvage chemotherapy for advanced gastric cancer (AGC).

Print Article Summary Cat 2 CME Report